| Literature DB >> 26006239 |
Wentao Zhang1, Ping Liang2, Weihua Wang3, Peng Dai4, Qin Wang5, Wei Yan6, Jinrong Zhao7, Jianbin Sun8, Yong Peng9, Daxiang Cui10, Zhen Yan11.
Abstract
Gastric adenocarcinoma (GAC) imposes a considerable health burden around the world. Gene variation in prostate stem cell antigen gene (PSCA) has been identified to be associated with GAC risk, while the results showed regional variation. To explore the influence of PSCA gene variation on its expression and GAC risk in the Northwest Chinese population, four single nucleotide polymorphisms (SNPs) of PSCA were genotyped in 476 GAC cases and 481 controls using MassARRAY system. Two SNPs of rs2294008 (C>T) and rs2976392 (G>A) were identified to be associated with GAC risk. rs2294008, rs2976392 and rs10216533 made up two statistically significant haplotypes (Hap-CGG and Hap-TAG). Additionally, PSCA expression was analyzed by quantitative real time PCR, immunohistochemistry and tissue microarray. The results showed that PSCA expression was decreased in GAC tissues compared with adjacent normal tissues. For normal tissues, PSCA expression was higher with Hap-TA than that with Hap-CG. For GAC tissues, the differentiation degree of Hap-TA was higher than that of Hap-CG. The expression distribution of PSCA in multiple human organs showed disparity. These results suggest that PSCA gene variation has a potential effect on its expression and GAC risk in the Northwest Chinese population.Entities:
Keywords: gastric adenocarcinoma; gene expression; haplotype; prostate stem cell antigen (PSCA); single nucleotide polymorphism (SNP)
Mesh:
Substances:
Year: 2015 PMID: 26006239 PMCID: PMC4463721 DOI: 10.3390/ijms160511648
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Basic information of candidate single nucleotide polymorphisms (SNPs).
| SNP ID | Position a | Location | Allele A/B b | HWE- |
|---|---|---|---|---|
| rs2294008 | 143,761,931 | 5'-UTR | T/C | 0.618 |
| rs3736001 | 143,762,807 | Exon 2 | A/G | 0.446 |
| rs2976392 | 143,762,932 | Intron 2 | A/G | 0.939 |
| rs10216533 | 143,763,690 | 3'-UTR | A/G | 0.266 |
a SNP position was obtained from NCBI map viewer; b A/B stands for minor/major alleles.
Characteristics of cases and controls.
| Variable | Case | Control |
| ||
|---|---|---|---|---|---|
| ( | ( | ||||
| Age, mean years (SD) | 57.1 | (11.5) | 56.4 | (11.8) | 0.334 a |
| Gender,
| |||||
| Male | 249 | (52.3) | 247 | (51.4) | 0.766 b |
| Female | 227 | (47.7) | 234 | (48.6) | |
a p values were calculated by Student’s t test; b p values were calculated by two-sided χ2 test.
Genotype frequency of prostate stem cell antigen (PSCA) variation and their association with gastric adenocarcinoma (GAC) risk.
| SNP ID | Genotype | No. (Frequency) | OR | (95% CI) |
| |||
|---|---|---|---|---|---|---|---|---|
| Case ( | Control ( | |||||||
| rs2294008 | CC | 227 | (47.8) | 261 | (54.4) | 1.00 | ||
| CT | 207 | (43.6) | 183 | (38.1) | 1.30 | (1.00–1.70) | 0.053 | |
| TT | 41 | (8.6) | 36 | (7.5) | 1.31 | (0.81–2.12) | 0.272 | |
| CT + TT | 248 | (52.2) | 219 | (45.6) | 1.30 | (1.01–1.68) | 0.042 * | |
| rs3736001 | GG | 382 | (80.6) | 402 | (83.6) | 1.00 | ||
| GA | 88 | (18.6) | 74 | (15.4) | 1.25 | (0.89–1.76) | 0.195 | |
| AA | 4 | (0.8) | 5 | (1.0) | 0.84 | (0.22–3.16) | 0.936 | |
| GA + AA | 92 | (19.4) | 79 | (16.4) | 1.23 | (0.88–1.71) | 0.229 | |
| rs2976392 | GG | 190 | (43.6) | 231 | (51.2) | 1.00 | ||
| GA | 208 | (47.7) | 184 | (40.8) | 1.37 | (1.04–1.81) | 0.024 * | |
| AA | 38 | (8.7) | 36 | (8.0) | 1.28 | (0.78–2.10) | 0.322 | |
| GA + AA | 246 | (56.4) | 220 | (48.8) | 1.36 | (1.04–1.77) | 0.023 * | |
| rs10216533 | GG | 237 | (53.6) | 256 | (54.4) | 1.00 | ||
| GA | 152 | (34.4) | 176 | (37.4) | 0.93 | (0.71–1.23) | 0.626 | |
| AA | 53 | (12.0) | 39 | (8.3) | 1.47 | (0.94–2.30) | 0.093 | |
| GA + AA | 205 | (46.4) | 215 | (45.7) | 1.03 | (0.79–1.34) | 0.824 | |
* Statistically significant (p < 0.05).
Figure 1Linkage disequilibrium (LD) and PSCA expression analysis. (A) LD of four SNPs in PSCA gene (rs2294008, rs3736001, rs2976392 and rs10216533); (B) LD of three SNPs in PSCA gene (rs2294008, rs2976392 and rs10216533). Values in squares were the pair-wise calculation of r2 (left) and D’ (right); (C) qRT-PCR results showed a significant decrease of PSCA mRNA levels in GAC tissues compared with their adjacent normal tissues (Normal vs. tumor: Hap-CG, 1.90-fold, p = 0.028; Hap-TA, 2.19-fold, p = 0.029). PSCA mRNA was higher with Hap-TA than that with Hap-CG in normal tissues (Hap-TA vs. Hap-CG: 20-fold, p = 0.042). Results were expressed as the ratio of the CT value of the PSCA gene transcript to that of β-actin. The mean ± standard error (SE) was shown. * p < 0.05, normal vs. tumor; ** p < 0.05, Hap-TA vs. Hap-CG; (D) Immunohistochemistry (IHC) results revealed that PSCA protein was expressed in differentiated gastric epithelial cells, but silencing in most of GAC tissues (p < 0.01). For normal tissues, PSCA expression was higher with Hap-TA than that with Hap-CG (p < 0.05). For GAC tissues, the differentiation degree of Hap-TA was higher than that of Hap-CG (p < 0.05), Scale bar = 20 μm, Magnification: ×400.
Haplotype frequency of PSCA variation and the association with GAC risk.
| Haplotype ID | Frequency a | OR (95% CI) | Fisher’s | Pearson’s | SNP No. and Haplotype | ||
|---|---|---|---|---|---|---|---|
| Case | Control | ||||||
|
| |||||||
| 1 | 0.67 | 0.72 | 0.83 | (0.67–1.01) | 0.065 | 0.065 | C–G |
| 2 | 0.32 | 0.28 | 1.21 | (0.99–1.48) | 0.065 | 0.065 | T–A |
| 3 | 0.64 | 0.71 | 0.78 | (0.64–0.96) | 0.020 * | 0.020 * | C–G–G |
| 4 | 0.29 | 0.28 | 1.08 | (0.87–1.33) | 0.478 | 0.478 | T–A–A |
| 5 | 0.04 | 0.00 | 12.28 | (3.75–40.27) | 0.00 * | 0.00 * | T–A–G |
a Only haplotypes with frequencies of ≥3% are shown; * Statistically significant (p < 0.05).
Figure 2Analysis of PSCA protein expression and distribution in human normal and tumor tissues by tissue microarray. (A) Digestive system. Esophagus, negative in both normal and tumor tissues; gastric, colon, liver and pancreas: Positive in normal, negative or down-regulated in tumor tissues; rectum: Negative in normal, and positive in tumor tissues, Scale bar = 20 μm, Magnification: ×200; (B) Non-digestive system. Bladder, cerebrum, kidney and skin: Positive in normal, and negative in tumor tissues; breast, lung, lymph node, ovary and prostate: Negative in normal, and positive in tumor tissues; uterus: Negative expression in both normal and tumor tissues, Scale bar = 20 μm, Magnification: ×200; (C) Semiquantitative comparison of PSCA immunostaining scores between normal and tumor tissues by IHC.